MedTrace Logo

Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness

NCT00127504 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-08-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).

Conditions

  • Onchocerciasis

Interventions

DRUG

Rifampin

DRUG

Azithromycin

Sponsors & Collaborators

Principal Investigators

  • Josef Amann, MD, MPH · CDC/NCID/DPD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Completion
2004-05-31

Countries

  • Guatemala

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00127504 on ClinicalTrials.gov